<DOC>
	<DOC>NCT00548002</DOC>
	<brief_summary>To study whether fluoroquinolone (trovafloxacin or levofloxacin), added to standard treatment, could reduce the high mortality and complication rates in Staphylococcus aureus bacteremia.</brief_summary>
	<brief_title>Combination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Endocarditis</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Trovafloxacin</mesh_term>
	<mesh_term>Alatrofloxacin</mesh_term>
	<criteria>Adult patients with at least 1 blood culture positive for Staphylococcus aureus were included within 1 to 7 days of blood culture sampling. age younger than 18 years imprisonment proven or suspected pregnancy breastfeeding, epilepsy another bacteremia during the previous 28 days polymicrobial bacteremia (_&gt;3 microbes) history of allergy to any quinolone antibiotic previous tendinitis during fluoroquinolone therapy prior fluoroquinolone use for more than 5 days before randomization positive culture for Staphylococcus aureus only from a central intravenous catheter neutropenia (&lt;0.5 x 109/L) or failure to supply an informed consent patients with bacteremia due to methicillinresistant S. aureus and a S. aureus strain resistant to any fluoroquinolone patients with meningitis at the time of randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Staphylococcus aureus</keyword>
	<keyword>bacteremia</keyword>
	<keyword>endocarditis</keyword>
	<keyword>sepsis</keyword>
	<keyword>fluoroquinolone</keyword>
	<keyword>rifampin</keyword>
	<keyword>levofloxacin</keyword>
	<keyword>trovafloxacin</keyword>
</DOC>